PeptideHelper.org
Your evidence-based peptide reference
Research reference only. Not medical advice. Most compounds are not FDA-approved. Consult a qualified clinician before any human use.

Weight Loss & Metabolic

Eloralintide

LY3841136

Classification: Amylin receptor agonist (investigational)

Mechanism: Long-acting amylin receptor agonist

Benefits: Weight loss; appetite control (Phase 1/2)

Evidence tier: Phase 1/2 · Availability: Investigational

Primary sources

  1. Billings LK et al. Eloralintide, a selective amylin receptor agonist for obesity — 48-week phase 2 trial. Lancet 2025. PMID 41207310
  2. Briere DA et al. Eloralintide (LY3841136), a novel amylin receptor agonist for obesity — discovery to clinical proof of concept. Mol Metab 2025. PMID 41109426

Loading interactive view…